TME Pharma Announces the End of the Convertible Debt Program With the Successful €1.48 Million Financing Intended for Buyback of All Outstanding Convertible Debt

Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the successful closing of a €1.48 million gross private placement financing with a group of new investors. The proceeds will be used to repurchase all the outstanding convertible bonds held by Atlas Special Opportunities, LLC (ASO), thereby ending TME Pharma's convertible bond financing program.

"This transaction marks a significant financial milestone for TME Pharma which fulfills our commitment to our shareholders to end the company's reliance on convertible bond financing and I am pleased to participate personally once again with the purchase of 363,637 shares in this transaction ¹," said Aram Mangasarian, CEO of TME Pharma. "The repurchase of all remaining convertible debt will eliminate the possibility of any further dilution from these instruments as well as the associated pressure on the share price, and we expect it to have a beneficial impact on the market valuation of TME Pharma enabling financing solutions with more favorable terms suited for our long-term strategic goals. We would like to extend our thanks to Atlas for their support over several years during which other funding alternatives were scarce. We also welcome our new investors who join us as we are reaching a crucial inflection point with our lead asset NOX-A12. Having just announced unprecedented survival data from our GLORIA trial in brain cancer², we are now poised to achieve our important targeted regulatory milestones, which include an approved IND and a decision on Fast Track Designation by the end of this quarter. With these achievements and a clear regulatory path in place, we should be in an excellent position to progress NOX-A12 through the next stages of its development, identify potential partners to work with us in bringing this innovative treatment to market as soon as possible, and to secure future financing with long-term investors."

Financing details
TME Pharma has received binding commitments for €1.48 million gross to purchase 6,727,270 ordinary shares at a price per share of €0.22 per share, at a 0.5% discount vs. the closing price per share on February 08, 2024. The transaction will be settled and closed by February 12, 2024. Investors, other than participating management members, will receive a commitment fee of 10% of the investment amount.